Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Fig. 1

a: Overall Survival for Melanoma Patients with or without Immune-Related Adverse Events, Comparing Group I (no irAE/or irAE before IL-2) with Group II (irAE During/After IL-2). (Autoimmune Disease = irAE), p < 0.0001. b: Overall Survival in Patients with mM, comparing Group I with Group II, removing those with irAEs due to CPI. (Autoimmune Disease = irAE), p < 0.0001

Back to article page